199 related articles for article (PubMed ID: 28104295)
1. Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.
Haltia UM; Andersson N; Yadav B; Färkkilä A; Kulesskiy E; Kankainen M; Tang J; Bützow R; Riska A; Leminen A; Heikinheimo M; Kallioniemi O; Unkila-Kallio L; Wennerberg K; Aittokallio T; Anttonen M
Gynecol Oncol; 2017 Mar; 144(3):621-630. PubMed ID: 28104295
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
Teoh D; Ayeni TA; Rubatt JM; Adams DJ; Grace L; Starr MD; Barry WT; Berchuck A; Murphy SK; Secord AA
Gynecol Oncol; 2011 Apr; 121(1):187-92. PubMed ID: 21208651
[TBL] [Abstract][Full Text] [Related]
5. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
[TBL] [Abstract][Full Text] [Related]
6. Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease.
Pilsworth JA; Cochrane DR; Neilson SJ; Moussavi BH; Lai D; Munzur AD; Senz J; Wang YK; Zareian S; Bashashati A; Wong A; Keul J; Staebler A; van Meurs HS; Horlings HM; Kommoss S; Kommoss F; Oliva E; Färkkilä AE; Gilks B; Huntsman DG
J Pathol Clin Res; 2021 May; 7(3):243-252. PubMed ID: 33428330
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
[TBL] [Abstract][Full Text] [Related]
8. Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells.
Waetzig R; Matthes M; Leister J; Penkivech G; Heise T; Corbacioglu S; Sommer G
Int J Med Sci; 2021; 18(1):137-149. PubMed ID: 33390782
[TBL] [Abstract][Full Text] [Related]
9. Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro.
Crosley P; Farkkila A; Jenner AL; Burlot C; Cardinal O; Potts KG; Agopsowicz K; Pihlajoki M; Heikinheimo M; Craig M; Fu Y; Hitt MM
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946730
[TBL] [Abstract][Full Text] [Related]
10. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
Treeck O; Wackwitz B; Haus U; Ortmann O
Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
[TBL] [Abstract][Full Text] [Related]
11. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
Konecny GE; Glas R; Dering J; Manivong K; Qi J; Finn RS; Yang GR; Hong KL; Ginther C; Winterhoff B; Gao G; Brugge J; Slamon DJ
Br J Cancer; 2009 Nov; 101(10):1699-708. PubMed ID: 19861960
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary.
Da Cruz Paula A; da Silva EM; Segura SE; Pareja F; Bi R; Selenica P; Kim SH; Ferrando L; Vahdatinia M; Soslow RA; Vidal A; Gatius S; Przybycin CG; Abu-Rustum NR; Matias-Guiu X; Rubin BP; Reis-Filho JS; DeLair DF; Weigelt B
Mod Pathol; 2020 Aug; 33(8):1606-1617. PubMed ID: 32203090
[TBL] [Abstract][Full Text] [Related]
13. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.
Chen B; Xu X; Luo J; Wang H; Zhou S
PLoS One; 2015; 10(6):e0129663. PubMed ID: 26061184
[TBL] [Abstract][Full Text] [Related]
15. A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer.
Pathak HB; Zhou Y; Sethi G; Hirst J; Schilder RJ; Golemis EA; Godwin AK
PLoS One; 2015; 10(12):e0144126. PubMed ID: 26637171
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR), HER2 and insulin-like growth factor-1 receptor (IGF-1R) status in ovarian adult granulosa cell tumours.
Higgins PA; Brady A; Dobbs SP; Salto-Tellez M; Maxwell P; McCluggage WG
Histopathology; 2014 Apr; 64(5):633-8. PubMed ID: 24206174
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
[TBL] [Abstract][Full Text] [Related]
18. Drug Sensitivity Screening and Targeted Pathway Analysis Reveal a Multi-Driver Proliferative Mechanism and Suggest a Strategy of Combination Targeted Therapy for Colorectal Cancer Cells.
Shen J; Li L; Yang T; Cheng N; Sun G
Molecules; 2019 Feb; 24(3):. PubMed ID: 30754629
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic insight into salinomycin mechanisms in breast cancer cell lines: synergistic effects with dasatinib and induction of estrogen receptor β.
Bellat V; Verchère A; Ashe SA; Law B
BMC Cancer; 2020 Jul; 20(1):661. PubMed ID: 32678032
[TBL] [Abstract][Full Text] [Related]
20. Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors-implications for therapeutic potential.
Färkkilä A; Zauli G; Haltia UM; Pihlajoki M; Unkila-Kallio L; Secchiero P; Heikinheimo M
Tumour Biol; 2016 Sep; 37(9):11909-11916. PubMed ID: 27067438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
